Literature DB >> 2643461

Hodgkin's disease: challenges for the future.

S A Rosenberg1.   

Abstract

Clinical investigators of Hodgkin's disease of the recent past have reason to be proud. Tens of thousands of individuals, many of them young, fertile, and productive, have been cured of their life-threatening disease. There are few better examples of the success and rewards of clinical oncology than in the control of Hodgkin's disease by improved diagnostic methods and the appropriate use of radiation and chemotherapy. Yet the clinical investigator of today cannot be satisfied with these successes. The treatment required for high cure rates remains empirical, difficult, and costly. The goal must be to prevent or reverse this fascinating disease, utilizing specific therapy designed from a knowledge of the cause and pathogenesis of the disease. There are sufficient biological clues and methodologies to predict that this will be possible, and in the decade of the 1990s!

Entities:  

Mesh:

Year:  1989        PMID: 2643461

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  [Trend analysis in Hodgkin disease mortality in the German Federal Republic 1955-1989: a comparison of log-linear models with descriptive standard methods].

Authors:  C Heuer; M Blettner
Journal:  Soz Praventivmed       Date:  1994

2.  Novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radical radiotherapy in localized stages (I-IIIA) of Hodgkin's disease. Early results in 100 consecutive patients. Pierre-et-Marie-Curie Group.

Authors:  B Hoerni; M B Orgerie; H Eghbali; C M Blanc; B David; J Rojouan; R Zittoun
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Hodgkin's disease mortality in Europe.

Authors:  C La Vecchia; F Levi; F Lucchini; S B Kaye; P Boyle
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.